Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 13/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12149497 | 0.88 | AHCY (0.68) | AHCYADORA2BDNMT1DNMT3BPDE8B | |
| SCHEMBL10431839 | 0.85 | AHCY (0.65) | AHCY | |
| SCHEMBL14635720 | 0.84 | AHCY (0.71) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL20191359 | 0.81 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL24686947 | 0.79 | ADORA2A (0.54) | AHCYADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL21057423 | 0.79 | AHCY (0.71) | AHCYADORA2BDNMT1DNMT3BPI4KA | |
| SCHEMBL9679135 | 0.78 | AHCY (0.80) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL21057391 | 0.78 | AHCY (0.53) | AHCYADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL21057389 | 0.78 | AHCY (0.53) | AHCYADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL21057371 | 0.78 | AHCY (0.53) | AHCYADORA2BPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |